Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab prefilled syringe in moderate to severe chronic plaque psoriasis
2011-006057-28Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis and plaque psoriasis comparing Secukinumab with Placebo (2 arms). Primary endpoints: PASI 75 response and Investigator's Global Assessment response. Started May 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2011-006057-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006057-28.